3BNC117 was manufactured by Celldex Therapeutics in CHO cells and purified by chromatography and sterile filtration. All the mAb preparations were endotoxin free. Cocktails of mAbs or single mAbs were administered to monkeys once or twice by the intravenous route at a dose of 10 mg/kg for each mAb. Monkeys were bled up to three times per week for viral loads. Immunologic and virologic data were generated blinded. All animal studies were approved by the appropriate
Institutional Animal Care and Use Committee (IACUC).
Circulating precursors of human CD1c+ and CD141+ dendritic cells.
Published in The Journal of experimental medicine, 2015-03-09, Volume 212
Brigham and Women's Hospital, The Rockefeller University, Hospital for Special Surgery, Columbia University, Partners HealthCare, Celldex Therapeutics
Gaëlle Breton, Jaeyop Lee, Yu Jerry Zhou, Joseph J Schreiber, Tibor Keler, Sarah Puhr, Niroshana Anandasabapathy, Sarah Schlesinger, Marina Caskey, Kang Liu, Michel C Nussenzweig
Two subsets of conventional dendritic cells (cDCs) with distinct cell surface markers and functions exist in mouse and human. The two subsets of cDCs are specialized antigen-presenting cells that initiate T cell immunity and tolerance. In the mouse, a migratory cDC precursor (...
Brigham and Women's Hospital Brigham and Women's Hospital The Rockefeller University The Rockefeller University Hospital for Special Surgery Hospital for Special Surgery Columbia University Columbia University Partners HealthCare Partners HealthCare Celldex Therapeutics Celldex Therapeutics
Its a tough call because we are in a major dynamic shift. Gild is making 4 billion a profit per quarter and they pay off that debt in a couple years who knows. CLDX has the most interesting dynamics and would be the one to go from 20 to 100 in a few months. That would mean Rindo approval and Gpnmb approved within next year. I think we see PD1 trials with Roche in triple negative as well. We are in a dynamic market and I think cancer will be a tough call in 10 years but mental illness is what cancer was 15 years ago. CLDX is always my number one pick but the big boys are very strong. Celg, Amgen, Novo, BMY and Roche but they could settle down. I want the next ALNY, ISIS and CLDX fits that bill but I want to diversify away from oncology. Actually XON could be the top dog of all in 5 years because they are a pure diversified company. I will probably go back and add Mack I had it at 3 and 4 and didn't keep enough of it or long enough. CLDN has the most potential to be go up 50 dollars in one day but be very careful.
Alot of good companies and these companies are better at what they do than 15 years ago. Please share any picks, I am always interested in market dynamics and picks.
Please share your list: I keep a wide range of options from long term to disease state. 60 percent of drugs in research are in oncology:
If anyone has any mental illness plays please share, mine are Roche and NERV you could throw in a Ludbeck but do not own.
All of these companies are worth a few minutes of glancing at. CLDX since 4, Gave Celladon two years ago before IPO and XON before IPO. TKMR at 6 and ISIS at 12.
Stock are more expensive now so be careful.
Europe: Ablynx, Galapagos and CeRenis Therapeutics.
5 or Under: Idera -Idra
Generic Companies: Sagent Pharmaceuticals
Rare Treatment: Rare Ultragenyx, (RARE), Fibrogen (FGEN)
Expensive: Blue, Kite.
Interesting and Expensive: Celladon, Esperion
Good Entry Points: Achaogen, Vascular Biogenics, Aquinox, NovoNorDisk
TOP Dog: Amgen, Roche, Gilead, Novo NorDisk,
Possible Huge Years: Gild, CLDX, XON, TGTX,
Great Science: Atra Atara Biosciences, Calitheria (CALA)
Worth Looking; Five Prime Therapuetics, ISIS, BMY, SNY,
Low dollar: APHB, SYN
Best in show if clinical trials positive: CLDX
Best Long Term: Amgen, Roche, GIld
Tekmira, REgulus and Prothena all worth looking up.
Best unknow sleepers: NERV, Addex therapeutics ( these are mental illness plays)
I can understand the trial delays to be honest. We are talking about triple negative breast cancer patients and looking for certain bio markers in our trials. This is new science using cell targets and combinations to get more significant results. Sure these trials early on seem confusing but if these things get approved there are going to be alot more studies or cocktail usage of these agents. EGFRV111 and GPNMB are leading targets for other cancers. I think the big question is for us is our we taking the long road by going after harder to treat cancers and would the short road in other trial areas have been more effective. There will be other studies for GPNMB so I would take the news as not a failure but a huge understanding on what we really are doing here. We as shareholders though have to take the blunt. Lets hope Rindo data is convincing and leading in the right direction. No one should expect a miracle for Glioblastoma.
http://www.hindawi.com/journals/jir/2014/796856/ They are being planned. Glioblastoma is going to need a full therapeutic process like most cancers but the brain area is even a harder area. I expect the REACT study to show continual efficacy and not off the chart numbers but something that continues to speak of a needed therapy or tool for GBM. Personally if the numbers and tumor responses are partially better than standard of care it would be hard not to seek approval. GBM is not friendly to overall survival numbers and progression free in previous trials this could be a small dilemma like most trials but it is more than evident there is a robust response in EGFR111 with titers and tumors response.
If they do not beat this quarter they have severe problems, did you see the well results this quarter and the one brought on late. If we fail we have a huge depletion problem. That is what I am really waiting to see. We had a good 15 to 20 wells with high IP rates
Who is playing the beat in results for WLL and KOG to increase WLL share price? I am thinking estimates are not baked into WLL based on current quarter. IF Peterson and company beat expectations handily that should send WLL into the 90's. Thoughts?
This has nothing more than to do with depletion rates and the share count both fears I had for owning this stock have come true again. Peterson is full of it.
What is so positive if we continue to see GPNMB show response in those with high expressions this could lead to shorter trials and quicker approval. Essentially we are identifying a paradigm shift.
Anybody have any guesses on 2nd quarter production numbers. We have seen alot of wells released with some high IP numbers? This quarter in my opinion is a big tell tell on the depletion of the wells and we are heading into next quarter with one year data on the projects.
I believe this is what is as well triggering more of the combination studies or mechanism of action combinations. The FDA hinted to this about a year or so ago and I believe it is coming as well. Essentially the FDA will say we just want to see one product with a mechanism of action on a target and not 5 or 6 look a likes.
These stock remain high on my Radar screen. TKMR Tekmira, this could be a 100 dollar stock one day.
Aquinox Pharmaceuticals and Conatus Pharmaceuticals. I would also include Arrow as well. What others are you seeing as a nice opportunity.
Conatus may be the super sleeper here I am learning more about their product but in multi billion dollar potential area.
I still like Idera and I would look at Mast Therapeutics for a high risk play. APHB is my favorite penny stock. SYN could have some serious potential if they can get funding and research inline.